Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial

The Lancet Gastroenterology and Hepatology

Volumn 1, Issue 3, 2016, Pages 196-206

  Buti, Maria ^a   Gane, Edward ^b   Seto, Wai Kay ^c   Chan, Henry L Y ^d   Chuang, Wan Long ^e   Stepanova, Tatjana ^f   Hui, Aric Josun ^g   Lim, Young Suk ^h   Mehta, Rajiv ⁱ   Janssen, Harry L A ^j   Acharya, Subrat K ^k   Flaherty, John F ^l   Massetto, Benedetta ^l   Cathcart, Andrea L ^l   Kim, Kyungpil ^l   Gaggar, Anuj ^l   Subramanian, G Mani ^l   McHutchison, John G ^l   Pan, Calvin Q ^m   Brunetto, Maurizia ⁿ   Izumi, Namiki ^o   Marcellin, Patrick ^p   more..

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b Auckland Clinical Studies   (New Zealand)

^c QUEEN MARY HOSPITAL   (Hong Kong)

^d CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^e KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^f Center of Modern Technologies   (Russian Federation)

^g ALICE HO MIU LING NETHERSOLE HOSPITAL   (Hong Kong)

^h Asan Medical Center   (South Korea)

ⁱ Surat Institute of Digestive Sciences (SIDS)   (India)

^j Toronto Liver Centre   (Canada)

^k ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^l GILEAD SCIENCES   (United States)

^m NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁿ UNIVERSITY HOSPITAL OF PISA   (Italy)

^o MUSASHINO RED CROSS HOSPITAL   (Japan)

^p BEAUJON HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; CREATININE; HEPATITIS B(E) ANTIGEN; LIPID; OSTEOCALCIN; PLACEBO; PROCOLLAGEN C PROTEINASE; TENOFOVIR ALAFENAMIDE; TENOFOVIR DISOPROXIL; VIRUS DNA; ADENINE; ANTIVIRUS AGENT; BIOLOGICAL MARKER; GS-7340; TENOFOVIR;

ADULT; ARTICLE; BODY MASS; BONE DENSITY; BONE TURNOVER; CHRONIC HEPATITIS B; CONTROLLED STUDY; CREATININE CLEARANCE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLOMERULUS FILTRATION RATE; HEADACHE; HEMATOLOGY; HEPATITIS B VIRUS; HEPATITIS B(E) ANTIGEN NEGATIVE CHRONIC HEPATITIS B VIRUS INFECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; UPPER RESPIRATORY TRACT INFECTION; URINALYSIS; X RAY BONE DENSITOMETER; ADOLESCENT; AGED; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; FOLLOW UP; IMMUNOLOGY; TREATMENT OUTCOME; VERY ELDERLY; VIROLOGY; VIRUS LOAD; YOUNG ADULT;

ADENINE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; BIOMARKERS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; TENOFOVIR; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84996538096     PISSN: 24681253     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2468-1253(16)30107-8     Document Type: Article

References (43)

1. 1 Trépo, C, Chan, HLY, Lok, A, Hepatitis B virus infection. Lancet 384 (2014), 2053–2063.
2. 2 Hadziyannis, SJ, Natural history of chronic hepatitis B in Euro-Mediterranean and African countries. J Hepatol 55 (2011), 183–191.
3. 3 Bonino, F, Brunetto, MR, Rizzetto, M, Will, H, Hepatitis B virus unable to secrete e antigen. Gastroenterology 100 (1991), 1138–1141.
4. 4 Fattovich, G, Bortolotti, F, Donato, F, Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 48 (2008), 335–352.
5. 5 Manesis, EK, HBeAg-negative chronic hepatitis B: from obscurity to prominence. J Hepatol 45 (2006), 343–346.
6. 6 Pungpapong, S, Kim, R, Poterucha, JJ, Natural history of hepatitis B virus infection: an update for clinicians. Mayo Clin Proc 82 (2007), 967–975.
7. 7 Brunetto, MR, Oliveri, F, Coco, B, et al. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long-term cohort study. J Hepatol 36 (2002), 263–270.
8. 8 Terrault, NA, Bzowej, NH, Chang, K-M, Hwang, JP, Jonas, MM, Murad, MH, AASLD guidelines for treatment of chronic hepatitis B. Hepatology 63 (2016), 261–283.
9. 9 European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 57 (2012), 167–185.
10. 10 Liaw, Y-F, Kao, J-H, Piratvisuth, T, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 6 (2012), 531–561.
11. 11 Delaney, WE 4th, Ray, AS, Yang, H, et al. Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob Agents Chemother 50 (2006), 2471–2477.
12. 12 Marcellin, P, Gane, E, Flisiak, R, et al. Long-term treatment with tenofovir disoproxil fumarate for chronic hepatitis B infection is safe and well tolerated and associated with durable virologic response with no detectable resistance: 8 year results from two phase 3 trials. Hepatology 60:suppl (2014), 313A–314A.
13. 13 Fung, S, Kwan, P, Fabri, M, et al. Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 146 (2014), 980–988.
14. 14 Fung, S, Hann, HWL, Elkhashab, M, et al. Long term efficacy and safety of tenofovir (TDF) in chronic hepatitis B patients (CHB) with documented lamivudine resistance (lam-r): 5 year results from a randomized, controlled trial. Hepatology 62:suppl (2015), 1184A–1185A.
15. 15 Babusis, D, Phan, TK, Lee, WA, Watkins, WJ, Ray, AS, Mechanism for effective lymphoid cell and tissue loading following oral administration of nucleotide prodrug GS-7340. Mol Pharm 10 (2013), 459–466.
16. 16 Murakami, E, Wang, T, Park, Y, et al. Implications of efficient hepatic delivery by tenofovir alafenamide (GS-7340) for hepatitis B virus therapy. Antimicrob Agents Chemother 59 (2015), 3563–3569.
17. 17 Agarwal, K, Fung, SK, Nguyen, TT, et al. Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection. J Hepatol 62 (2015), 533–540.
18. 18 Ruane, PJ, DeJesus, E, Berger, D, et al. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults. J Acquir Immune Defic 63 (2013), 449–455.
19. 19 Sax, PE, Wohl, D, Yin, MT, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet 385 (2015), 2606–2615.
20. 20 Mills, A, Arribas, JR, Andrade-Villanueva, J, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. Lancet Infect Dis 16 (2016), 43–52.
21. 21 Marcellin, P, Heathcote, EJ, Buti, M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 359 (2008), 2442–2455.
22. 22 Hadziyannis, SJ, Tassopoulos, NC, Heathcote, EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 348 (2003), 800–807.
23. 23 Poynard, T, Imbert-Bismut, F, Munteanu, M, et al. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol, 3, 2004, 8.
24. 24 Prati, D, Taioli, E, Zanella, A, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 137 (2002), 1–10.
25. 25 Lok, AS, McMahon, B, Chronic hepatitis B: an update. Hepatology, 50, 2012, 662.
26. 26 Marcellin, P, Gane, E, Buti, M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. Lancet 381 (2013), 468–475.
27. 27 Lai, CL, Shouval, D, Lok, AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 354 (2006), 1011–1020.
28. 28 Lai, CL, Gane, E, Liaw, YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 357 (2007), 2576–2588.
29. 29 Chan, HLY, Fung, S, Seto, WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol, 2016 published online Sept 22. http://dx.doi.org/10.1016/S2468-1253(16)30024-3.
30. 30 Cassetti, I, Madruga, JV, Suleiman, JM, et al. The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naïve HIV-1-infected patients. HIV Clin Trials 8 (2007), 164–172.
31. 31 Bernardino, JI, Mocroft, A, Mallon, PW, et al. Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial. Lancet HIV 2 (2015), e464–e473.
32. 32 Brown, TT, Moser, C, Currier, JS, et al. Changes in bone mineral density after initiation of antiretroviral treatment with tenofovir disoproxil fumarate/emtricitabine plus atazanavir/ritonavir, darunavir/ritonavir, or raltegravir. J Infect Dis 212 (2015), 1241–1249.
33. 33 Gill, US, Zissimopoulos, A, Al-Shamma, S, et al. Assessment of bone mineral density in tenofovir-treated patients with chronic hepatitis B: can the fracture risk assessment tool identify those at greatest risk?. J Infect Dis 211 (2015), 374–382.
34. 34 Chen, CH, Lin, CL, Kao, CH, Association between chronic hepatitis B virus infection and risk of osteoporosis: a nationwide population-based study. Medicine (Baltimore), 94, 2015, e2276.
35. 35 Maggi, P, Montinaro, V, Leone, A, et al. Bone and kidney toxicity induced by nucleotide analogues in patients affected by HBV-related chronic hepatitis: a longitudinal study. J Antimicrob Chemother 70 (2015), 1150–1154.
36. 36 Cooper, RD, Wiebe, N, Smith, N, Keiser, P, Naicker, S, Tonelli, M, Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis 51 (2010), 496–505.
37. 37 Hall, AM, Hendry, BM, Nitsch, D, Connolly, JO, Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence. Am J Kidney Dis 57 (2011), 773–780.
38. 38 Viganò, M, Brocchieri, A, Spinetti, A, et al. Tenofovir-induced Fanconi syndrome in chronic hepatitis B monoinfected patients that reverted after tenofovir withdrawal. J Clin Virol 61 (2014), 600–603.
39. 39 Gracey, DM, Snelling, P, McKenzie, P, Strasser, SI, Tenofovir-associated Fanconi syndrome in patients with chronic hepatitis B monoinfection. Antivir Ther 18 (2013), 945–948.
40. 40 Gara, N, Zhao, X, Collins, MT, et al. Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B. Aliment Pharmacol Ther 35 (2012), 1317–1325.
41. 41 Hall, AM, Edwards, SG, Lapsley, M, et al. Subclinical tubular injury in HIV-infected individuals on antiretroviral therapy: a cross-sectional analysis. Am J Kidney Dis 54 (2009), 1034–1042.
42. 42 Mallet, V, Schwarzinger, M, Vallet-Pichard, A, et al. Effect of nucleoside and nucleotide analogues on renal function in patients with chronic hepatitis B virus monoinfection. Clin Gastroenterol Hepatol 13 (2015), 1181–1188.
43. 43 Bernard, AM, Moreau, D, Lauwerys, R, Comparison of retinol-binding protein and beta 2-microglobulin determination in urine for the early detection of tubular proteinuria. Clin Chim Acta 126 (1982), 1–7.